{"id":66778,"date":"2026-04-27T08:02:24","date_gmt":"2026-04-27T02:32:24","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=66778"},"modified":"2026-04-27T08:02:26","modified_gmt":"2026-04-27T02:32:26","slug":"right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/","title":{"rendered":"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/RlqGHUQnk98?si=MULxc2fPv9JNLd-z\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">Right ventricular (RV) dysfunction is a clinical and hemodynamic syndrome resulting from impaired RV filling or ejection, often leading to systemic venous congestion and low cardiac output. Contemporary management focuses on a physiology-oriented approach that balances preload optimization, afterload reduction, and enhancement of myocardial contractility.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Diagnostic Framework<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The diagnosis of RV dysfunction has transitioned from simple visual estimation to quantitative multi-modality imaging and bedside assessment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1. First-Line Imaging: Echocardiography<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Echocardiography remains the primary diagnostic tool due to its accessibility and comprehensive hemodynamic data.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Conventional Parameters:<\/strong> Tricuspid Annular Plane Systolic Excursion (<strong>TAPSE<\/strong>), Fractional Area Change (<strong>FAC<\/strong>), and Doppler-derived S&#8217; wave are standard for assessing longitudinal and global function.<\/li>\n\n\n\n<li class=\"\"><strong>Speckle-Tracking Echocardiography (STE):<\/strong> <a href=\"https:\/\/www.frontiersin.org\/journals\/cardiovascular-medicine\/articles\/10.3389\/fcvm.2023.1030864\/full\" type=\"link\" id=\"https:\/\/www.frontiersin.org\/journals\/cardiovascular-medicine\/articles\/10.3389\/fcvm.2023.1030864\/full\">Right ventricular free-wall longitudinal strain<\/a> (<strong>RV-fwLS<\/strong>) is more sensitive than RVEF or TAPSE for detecting subclinical dysfunction and predicting clinical outcomes.<\/li>\n\n\n\n<li class=\"\"><strong>3D Echocardiography:<\/strong> Provides a more accurate quantification of RV volumes and ejection fraction (RVEF) without the geometric assumptions required by 2D imaging.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2. Advanced Modalities<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Cardiac Magnetic Resonance (CMR):<\/strong> The gold standard for quantifying RV mass, volumes, and RVEF. It is particularly valuable for identifying infiltrative diseases (e.g., amyloidosis) and tissue characterization.<\/li>\n\n\n\n<li class=\"\"><strong>Point-of-Care Ultrasound (POCUS):<\/strong> Rapid bedside assessment of the inferior vena cava (IVC) and lung B-lines (indicating congestion) allows for real-time monitoring of therapeutic response and volume status.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><a href=\"https:\/\/www.jhltopen.org\/article\/S2950-1334(24)00153-8\/fulltext\" type=\"link\" id=\"https:\/\/www.jhltopen.org\/article\/S2950-1334(24)00153-8\/fulltext\">Therapeutic Options<\/a><\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Therapeutic strategies are dictated by the chronicity of the failure and the underlying etiology, specifically focusing on the <strong>RV-PA (Pulmonary Artery) Coupling<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1. Acute Management Principles<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Management of acute RV failure aims to restore systemic perfusion and prevent a &#8220;downward spiral&#8221; of ischemia and worsening afterload.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Preload Optimization:<\/strong> Judicious fluid management is critical. While volume resuscitation is indicated in hypovolemia, excessive fluids in a dilated RV can cause &#8220;ventricular interdependence,&#8221; where the interventricular septum shifts leftward, reducing left ventricular (LV) filling.<\/li>\n\n\n\n<li class=\"\"><strong>Afterload Reduction:<\/strong> In acute pulmonary embolism or pulmonary hypertension (PH), reducing pulmonary vascular resistance (PVR) is essential. Options include inhaled nitric oxide or prostacyclins.<\/li>\n\n\n\n<li class=\"\"><strong>Inotropic Support:<\/strong> Dobutamine or milrinone may be used to enhance contractility, though care must be taken to avoid systemic hypotension.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2. Chronic Management &amp; Emerging Therapies<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Guideline-Directed Medical Therapy (GDMT):<\/strong> While traditionally focused on the left heart, recent evidence supports the use of Sodium-Glucose Cotransporter-2 inhibitors (<strong>SGLT2i<\/strong>) and mineralocorticoid receptor antagonists (<strong>MRAs<\/strong>) for overall heart failure management, which may indirectly benefit RV function through improved LV hemodynamics.<\/li>\n\n\n\n<li class=\"\"><strong>Advanced PAH Therapies:<\/strong> Novel agents like <strong>sotatercept<\/strong> (an activin signaling inhibitor) have shown significant promise in recent trials (STELLAR and ZENITH) for reducing PVR and improving RV-PA coupling in pulmonary arterial hypertension.<\/li>\n\n\n\n<li class=\"\"><strong>Mechanical Circulatory Support (MCS):<\/strong> For refractory RV failure, temporary RV assist devices (RVADs) or extracorporeal membrane oxygenation (ECMO) are utilized as a bridge to recovery or transplantation.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3. Interventional Strategies<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Valvular Correction:<\/strong> Transcatheter edge-to-edge repair (TEER) for severe tricuspid regurgitation is increasingly used to reduce chronic volume overload on the RV.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2213558\" type=\"link\" id=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2213558\">STELLAR Trial<\/a><\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The pivotal Phase 3 STELLAR trial was the foundation for the FDA\u2019s approval of sotatercept on <strong>March 26, 2024<\/strong>. The study demonstrated that adding sotatercept to background therapy significantly improved 6-minute walk distance (6MWD) and reduced the risk of death or clinical worsening.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2415160\" type=\"link\" id=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2213558\">ZENITH Trial<\/a><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Presented and published in early 2025, the <strong>ZENITH trial<\/strong> specifically targeted high-risk PAH patients (those on maximal therapy with a high mortality risk). The trial was stopped early due to overwhelming efficacy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39466552\/\">Sotatercept: The First FDA-Approved Activin A Receptor IIA Inhibitor<\/a><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As mentioned, Sotatercept has been shown to improve 6 minute walk distance in patients with PAH at 24 weeks. More studies are needed to assess the mortality benefit. Currently the limitations are the high cost and unknown long-term effects. Adverse effects noted in the trials were epistaxis, telangiectasia, increased hemoglobin, hematocrit, red blood cell levels, and dizziness, compared to placebo.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n","protected":false},"excerpt":{"rendered":"<p>Right ventricular (RV) dysfunction is a clinical and hemodynamic syndrome resulting from impaired RV filling or ejection, often leading to systemic venous congestion and low cardiac output. Contemporary management focuses on a physiology-oriented approach that balances preload optimization, afterload reduction, and enhancement of myocardial contractility. Diagnostic Framework The diagnosis of RV dysfunction has transitioned from [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":66785,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-66778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Right ventricular (RV) dysfunction is a clinical and hemodynamic syndrome resulting from impaired RV filling or ejection, often leading to systemic venous congestion and low cardiac output. Contemporary management focuses on a physiology-oriented approach that balances preload optimization, afterload reduction, and enhancement of myocardial contractility. Diagnostic Framework The diagnosis of RV dysfunction has transitioned from [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T02:32:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-27T02:32:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1201\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH\",\"datePublished\":\"2026-04-27T02:32:24+00:00\",\"dateModified\":\"2026-04-27T02:32:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/\"},\"wordCount\":620,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/\",\"name\":\"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg\",\"datePublished\":\"2026-04-27T02:32:24+00:00\",\"dateModified\":\"2026-04-27T02:32:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg\",\"width\":1201,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/","og_locale":"en_US","og_type":"article","og_title":"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH - All About Cardiovascular System and Disorders","og_description":"Right ventricular (RV) dysfunction is a clinical and hemodynamic syndrome resulting from impaired RV filling or ejection, often leading to systemic venous congestion and low cardiac output. Contemporary management focuses on a physiology-oriented approach that balances preload optimization, afterload reduction, and enhancement of myocardial contractility. Diagnostic Framework The diagnosis of RV dysfunction has transitioned from [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-04-27T02:32:24+00:00","article_modified_time":"2026-04-27T02:32:26+00:00","og_image":[{"width":1201,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH","datePublished":"2026-04-27T02:32:24+00:00","dateModified":"2026-04-27T02:32:26+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/"},"wordCount":620,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/","url":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/","name":"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg","datePublished":"2026-04-27T02:32:24+00:00","dateModified":"2026-04-27T02:32:26+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Right-Ventricular-Dysfunction-Diagnosis-and-Therapeutic-Options-1.jpg","width":1201,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/right-ventricular-dysfunction-diagnosis-and-therapeutic-options-sotatercept-activin-iia-inhibitor-for-pah\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Right Ventricular Dysfunction: Diagnosis and Therapeutic Options; Sotatercept: Activin IIA inhibitor for PAH"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=66778"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66778\/revisions"}],"predecessor-version":[{"id":66786,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66778\/revisions\/66786"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/66785"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=66778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=66778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=66778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}